CROP Infrastructure Corp. (CSE:CROP, OTC:CRXPF) (“CROP” or the “Company”) is pleased to announce it has signed a definitive licensing agreement for US distribution rights and for the exclusive Italian rights to The Yield Growth Corp.’s proprietary cosmetic and therapeutic products that are formulated for infusion with cannabis.

The agreement grants CROP the license to infuse Yield Growth subsidiary Juve Wellness Inc.’s products with high CBD / low THC cannabis and exclusively distribute the products in Italy for three years, with  annual renewals on achieving certain sales. Juve has agreed to customize branding and labelling of its products for CROP for the Italian market.


CROP is also acquiring the non-exclusive rights to distribute the line of hemp root oil based Juve products in the United States.   Juve and CROP have agreed to negotiate exclusively for a period of 30 days for the possible exclusive rights to infuse the products with cannabis and distribute them in California and Washington.

Juve has developed a modern wellness line inspired by Ayurveda, an ancient and effective medical system that uses plant based ingredients for healing and wellness. Juve has registered 25 of its products with Health Canada and has submitted 10 provisional patent applications in the United States for its formulas and extraction process.  Juve plans to launch its products for Canadian retail distribution in early 2019.  The line includes over 50 cosmetic and therapeutic products based on proprietary completely organic formulations which have been designed to be infused with Cannabidiol (CBD) and Tetrahydrocannabinol (THC).  The line includes face and body products customized according to specific body biology, including daily ritual oils, moisturizers, face mists, bath salts, soap and face masks.  Therapeutic products include sunscreen, anti-aging serum, topical formulations for treatment of inflammation and chronic pain, sports spray, teas and capsules.  Sexual lubricant, massage oils, lip balm, deodorant and sunscreen are also included in the CROP licensing package.

According to a study by Arcview Market Research and its research partner BDS Analytics, by 2027 worldwide sales of legal cannabis are forecast to reach $57 billion. During that period, spending in North America is expected to leap from $9.2 billion to $47.3 billion driven mainly by recreational use. The fastest cannabis market growth is expected to come from outside North America, especially Europe where the main growth driver will be medical applications.  Medical cannabis use will be fed by $1.3 trillion estimated annual government-subsidized healthcare spending. The structure of the healthcare industry is expected to make Europe the number one medical cannabis market in the world.

“We are thrilled to be aligned with CROP Infrastructure Corp. to infuse with cannabis and distribute our extensive line of wellness products throughout Italy,” says Penny Green, President and CEO of Yield Growth. “CROP is at the forefront of the burgeoning Cannabis industry as it now seeks to move beyond the State of Washington and California with this deal as its entry into the European cannabis market.”

Michael Yorke, CEO of CROP Infrastructure stated, “This acquisition will be complementary to our efforts of expanding our operations into Europe. We also look forward to bringing this suite of new offerings to our tenant growers and their distribution in Washington and California and as we continue to expand into other States.”

Under the terms of the agreement, Yield Growth will receive $1 million for the Italian license and distribution rights through the issuance of 2,500,000 units of CROP at a deemed price of $0.40 per unit.  Each unit will consist of one common share of CROP and one half warrant to purchase one additional common share at an exercise price of $0.55 per share for eighteen months. The shares will be subject to escrow provisions which will release the stock over a period of three years. In addition to the $1 million unit issuance to Yield Growth, CROP intends to complete a private placement for $200K worth of additional units to pay for marketing expenses.

About The Yield Growth Corp.

The Yield Growth Corp. is a wellness asset growth company cultivating high value companies, brands and assets centered around the legal cannabis industry and its key players. Yield Growth is committed to providing a highly personalized, informed and value-added customer experience within the wellness industry. Yield is a partially owned subsidiary of Glance Technologies Inc. (CSE:GET) (OTCQB:GLNNF) (FKT:GJT).

For more information about The Yield Growth Corp., visit yieldgrowth.com or contact info@yieldgrowth.com.

About CROP Infrastructure Corp.

CROP Infrastructure Corp. is engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. CROP’s portfolio of projects includes greenhouse facilities in California and Washington State.

For more information about CROP Infrastructure Corp.

Michael Yorke – Director
E-mail: info@cropcorp.com
Phone: (604) 484-4206

Disclaimer for Forward-Looking Information
Certain statements in this press release are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the purchase, development and leasing of projects, commencement of construction of additional greenhouses, estimated Tenant production of product, the pursuit of new opportunities and the expansion of CROP’s portfolio. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the Company’s ability to execute on its business plan, raise additional funds as and when required, legal and political risks regarding the cannabis industry, including the changes of municipal, state, provincial and federal laws thereof, the risk that Humboldt may require further capital to execute on its expansion plans and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Click here to connect with CROP Infrastructure Corp. (CSE:CROP, OTC:CRXPF) for an Investor Presentation.

Source: globenewswire.ca

  • Company surpassed 5,600 patient prescriptions for its medical cannabis products in Colombia . Prescriptions filled increased over 450% in Q3 2020 over Q2 2020
  • Khiron declared a National Strategic Project by the Government of Colombia , simplifying and accelerating administration and processes for the Company in executing strategic projects in Colombia and for export
  • Subsequent to the quarter, the Company completed a bought deal financing on November 26, 2020 , selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000 CAD
  • Khiron signed partnerships with 15 clinics and health centres in Colombia , extending education and sales reach further across the country
  • As a result of the Company’s Doctor Zerenia TM telehealth platform more than 25% of the Company’s medical cannabis prescriptions came from outside of Bogota , expanding geographic presence of its Colombian clinics
  • Company achieved first sales of High CBD medical cannabis through private pharmacies in Peru . Additional approval received from Peru’s drug regulatory authority for Company’s High THC cannabis, with first prescriptions anticipated in Q1 2021
  • Expanded medical cannabis E-Learning platform to UK market in partnership with Medical Cannabis Clinicians Society (“MCCS”)
  • Entered an exclusive partnership with Rappi SAS, Latin America’s largest home multi-vertical app platform to distribute the Company’s CPG product portfolio, introducing Kuida products to Rappi users across the LatAm region
  • Signed agreement to distribute the Company’s Kuida TM CBD skincare brand through pharmacy, beauty retail and online markets serving the Hong Kong territory, with first orders expected in Q4 2020
  • Prudent cash use of $5 million in Q3 2020, compared with $4 million in Q2 2020, $12 million in Q1 2020 and $10 million in Q4 2019

 Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announced today its financial results for the quarter ended September 30, 2020 . These filings are available for review on the Company’s SEDAR profile at www.sedar.com All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less